Pain Management Devices Market (By Product Type: Electrical Stimulation Devices, Radiofrequency (RF) Ablation Devices, Neuromodulation Devices, Infusion Pumps; By Application: Musculoskeletal, Brain, Cancer, Neuropathy, and Others; By End User: Physiotherapy Centers, Hospitals and Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
The global pain management devices market was valued at US$ 4.46 billion in 2022 and is expected to reach over US$ 10.91 billion by 2032, poised to grow at a CAGR of 9.4% during the forecast period 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The pain management is a discipline of medicine that aims to alleviate the suffering of chronic pain patients. The acute pain has a quick onset of action, whereas chronic pain lasts longer and necessitates treatment. The pain management devices are medical devices used to treat various types of pain, including cancer pain, neuropathic pain, and musculoskeletal pain.
There are many different types of pain management devices in the market, such as analgesic infusion pumps, spinal cord stimulators, neurostimulation devices, and ablation devices. The increased geriatric population, the surge in consumer awareness about pain management devices, rise in prevalence of chronic pain, launch of innovative products, and increased research and development (R&D) are all driving the global pain management devices market growth during the forecast period.
The other factors that contribute to the pain management devices market growth includes an increase in the usage of pain management devices for the treatment of chronic pain, coupled with an increase in demand for pain management devices in emerging nations.
Due to the ageing population, there has been an increase in the use of pain management devices in recent years. The increased cancer incidences, the rising frequency of lifestyle-related diseases, and rising neuropathic disorders are only a few of the important drivers propelling the global pain management devices growth during the forecast period.
Furthermore, rising healthcare awareness and spending are driving the growth of pain management devices market. However, the adverse effects such as skin hypersensitivity and hyperpigmentation, as well as the availability of substitutes such as pain reliever drugs are limiting the growth of global pain management devices market.
The global pain management devices market would benefit from technological advancements in pain management devices. The high cost of manufacturing pain management devices, on the other hand could pose a threat to the growth of global pain management devices market during the forecast period.
The global pain management devices market has observed an increased in demand for spinal cord stimulation devices to treat chronic pain, refractory pain, and neuropathic pain. This factor will drive the market growth for pain management devices.
Report Coverage | Details |
Market Size in 2023 | US$ 4.86 Billion |
Growth Rate from 2023 to 2032 | CAGR of 9.4% |
Revenue Projection by 2032 | US$ 10.91 Billion |
Largest Market | North America |
Fastest Growing Market | Europe |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Companies Mentioned | Nevro Corporation, LivaNova, SPR Therapeutics, Boston Scientific Corporation, Abbott, DJO Global LLC, Medtronic, Omron Healthcare Inc., Smiths Medical, Melsungen AG |
Based on theproduct type, the neuromodulation devices dominate the market with revenue share of 60% in 2022. The rising prevalence of chronic ailments, as well as the limits of pharmaceutical medications in efficiently treating these diseases, has paved the way for new neuromodulation techniques. The functional capabilities of various nerves in the human body, as well as the consequences of electrical stimulation of these nerves for the treatment of various illnesses, are continually being investigated. As a result, new approaches and technology for detecting and treating chronic illnesses have emerged.
On the other hand, the radiofrequency (RF) ablation devices segment is expected to grow at rapid pace during the forecast period. The rise in the prevalence of cardiovascular disorders such as atrial fibrillation, the incidence of patients suffering from pain and cancer, and the need for minimally invasive procedures are all driving the growth of radiofrequency (RF) ablation devices segment. The utilization of ultrasonic ablation technology in radiofrequency (RF) ablation devices is also helping to boost their demand in the market.
Based on the application, the neuropathy held largest revenue share of 32% in 2022. The growth of the segment can be attributed to the rising prevalence of the target group as well as increased industry initiatives for the growth and development of the pain management devices market.
On the other hand, the cancer segment is expected to grow at rapid pace during the forecast period. The rising number of cancer cases has resulted in a rise in the demand for pain management devices to relieve the pain produced by nerve compression, which is primarily caused by tumor compression and other variables that vary depending on the stage of disease.
Based on the end user, the physiotherapy centers dominate the pain management devices market during the forecast period. The pain management devices are highly used in physiotherapy centers. The rehabilitation, health promotion, and injury prevention are all aspects of physiotherapy. The treatment requires high quality of pain management devices.
On the other hand, the hospitals and clinics is expected to grow at rapid pace during the forecast period. The pain management devices are used in the hospitals and clinics on a large scale. The cancer patients need regular checkups. The cancer specialists use pain management devices tremendously for the treatment of various kind of cancers.
Based on the region, the North America segment accounted revenue share of 47% in 2022. The factors such as favorable healthcare facilities and infrastructure are driving the growth of pain management devices market in North America region. In addition, the rising government initiatives are also contributing towards growth of market in this region.
On the other hand, the Europe is estimated to be the most opportunistic segment during the forecast period. This is attributed to the rise in investments in research and development (R&D) for advanced technological solutions in healthcare industry. Moreover, the market is highly influenced by several trade agreements in the region.
Key Companies & Market Share Insights
To increase their market reach, the key market players have launched a number of strategic activities, including technology innovation, partnerships, regional growth, and mergers and acquisitions. Medtronic, for example, announced the commercial introduction of the InterStim Micro Neurostimulator, a Food and Drug Administration (FDA) approved neurostimulator, in August 2020.
Segments Covered in the Report
By Product Type
By Application
By End User
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pain Management Devices Market
5.1. COVID-19 Landscape: Pain Management Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pain Management Devices Market, By Product
8.1. Pain Management Devices Market, by Product Type, 2023-2032
8.1.1. Electrical Stimulation Devices (TENS, Others)
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. Radiofrequency (RF) Ablation Devices
8.1.2.1. Market Revenue and Forecast (2021-2032)
8.1.3. Neuromodulation Devices
8.1.3.1. Market Revenue and Forecast (2021-2032)
8.1.4. Infusion Pumps (Intrathecal Infusion Pumps, External Infusion Pumps)
8.1.4.1. Market Revenue and Forecast (2021-2032)
Chapter 9. Global Pain Management Devices Market, By Application
9.1. Pain Management Devices Market, by Application, 2023-2032
9.1.1. Musculoskeletal
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. Brain
9.1.2.1. Market Revenue and Forecast (2021-2032)
9.1.3. Cancer
9.1.3.1. Market Revenue and Forecast (2021-2032)
9.1.4. Neuropathy
9.1.4.1. Market Revenue and Forecast (2021-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2032)
Chapter 10. Global Pain Management Devices Market, By End User
10.1. Pain Management Devices Market, by End User, 2023-2032
10.1.1. Physiotherapy Centers
10.1.1.1. Market Revenue and Forecast (2021-2032)
10.1.2. Hospitals and Clinics
10.1.2.1. Market Revenue and Forecast (2021-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2032)
Chapter 11. Global Pain Management Devices Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2032)
11.1.2. Market Revenue and Forecast, by Application (2021-2032)
11.1.3. Market Revenue and Forecast, by End User (2021-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2032)
11.1.4.3. Market Revenue and Forecast, by End User (2021-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2032)
11.1.5.3. Market Revenue and Forecast, by End User (2021-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2032)
11.2.2. Market Revenue and Forecast, by Application (2021-2032)
11.2.3. Market Revenue and Forecast, by End User (2021-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2032)
11.2.4.3. Market Revenue and Forecast, by End User (2021-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2032)
11.2.5.3. Market Revenue and Forecast, by End User (2021-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2032)
11.2.6.3. Market Revenue and Forecast, by End User (2021-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2032)
11.2.7.3. Market Revenue and Forecast, by End User (2021-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2032)
11.3.2. Market Revenue and Forecast, by Application (2021-2032)
11.3.3. Market Revenue and Forecast, by End User (2021-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2032)
11.3.4.3. Market Revenue and Forecast, by End User (2021-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2032)
11.3.5.3. Market Revenue and Forecast, by End User (2021-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2032)
11.3.6.3. Market Revenue and Forecast, by End User (2021-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2032)
11.3.7.3. Market Revenue and Forecast, by End User (2021-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2032)
11.4.2. Market Revenue and Forecast, by Application (2021-2032)
11.4.3. Market Revenue and Forecast, by End User (2021-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2032)
11.4.4.3. Market Revenue and Forecast, by End User (2021-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2032)
11.4.5.3. Market Revenue and Forecast, by End User (2021-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2032)
11.4.6.3. Market Revenue and Forecast, by End User (2021-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2032)
11.4.7.3. Market Revenue and Forecast, by End User (2021-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2032)
11.5.2. Market Revenue and Forecast, by Application (2021-2032)
11.5.3. Market Revenue and Forecast, by End User (2021-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2032)
11.5.4.3. Market Revenue and Forecast, by End User (2021-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2032)
11.5.5.3. Market Revenue and Forecast, by End User (2021-2032)
Chapter 12. Company Profiles
12.1. Nevro Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. LivaNova
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. SPR Therapeutics
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Boston Scientific Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Abbott
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. DJO Global LLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Medtronic
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Omron Healthcare Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Smiths Medical
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Melsungen AG
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client